307538-20-1

Basic information

• Product Name: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
• Synonyms: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
• CAS NO: 307538-20-1
• Molecular Weight: 334.603
• Mol File: 307538-20-1.mol

Chemical Properties

• CAS DataBase Reference: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(307538-20-1)
• EPA Substance Registry System: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(307538-20-1)

Safety Data

• Hazardous Substances Data: 307538-20-1(Hazardous Substances Data)

Upstream product

• 16313-66-9 5-bromoanthranilamide 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 1041612-51-4 N-(3-chlorophenyl)-6-(4-(morpholinosulfonyl)phenyl)quinazolin-4-amine 

Relevant articles and documents

COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER

A combination comprising a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator. Methods for the prevention and treatment of a cancer comprises administering to a subject in need thereof, a therapeutically effective amount of a combination, the combination comprising: a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator.

Synthesis and in vitro cytotoxicity of the 4-(Halogenoanilino)-6-bromoquinazolines and their 6-(4-fluorophenyl) substituted derivatives as potential inhibitors of epidermal growth factor receptor tyrosine kinase

Series of the 2-unsubstituted and 2-(4-chlorophenyl)–substituted 4-anilino-6-bromoquinazolines and their 6-(4-fluorophenyl)–substituted derivatives were evaluated for in vitro cytotoxicity against MCF-7 and HeLa cells. The 2-unsubstituted 4-anilino-6-brom

SMALL MOLECULE INHIBITORS OF EGFR AND PI3K

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.

Discovery, synthesis, and biological evaluation of thiazoloquin(az)olin(on)es as potent CD38 inhibitors

A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasm

Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5

A high-throughput cell-based screen identified a series of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of metabotropic glutamate receptor 5 (mGlu5). This Letter describes the SAR of this series and the profile of selected

METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER

This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF BODY COMPOSITION DISORDERS

This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.